Skip to main content
. Author manuscript; available in PMC: 2009 Jul 9.
Published in final edited form as: Circulation. 2006 Jul 31;114(6):574–582. doi: 10.1161/CIRCULATIONAHA.105.592550

Figure 1. Functional assessment of Ro-32-0432 and Ro-31-8220 in the heart.

Figure 1

(A) Chemical structures of Ro-32-0432 and Ro-31-8220 used in this study. (B) Western blot analysis for phosphoMARCKS protein to analyze the inhibitory ability of Ro-32-0432 (50 nM) and Ro-31-8220 (50 nM) compared with vehicle (Veh) in cultured neonatal rat cardiomyocytes infected with AdPKCα and treated with PMA. (C) Isolated working heart preparation of cardiac contractility (+dP/dt) *P=0.0052 or (D) left ventricular pressure developed following vehicle infusion (N=3) or Ro-32-0432 (N=4) at 8 × 10−8 µg/ml *P=0.0012. Statistical significance was assessed by two-sample t tests.